_edited.png)
Why Cannabis Should Leave Schedule I, Now
Updated: Oct 3
Fast Facts
Who / Where: NORML; U.S. Department of Health and Human Services (HHS); United States
What changed: NORML publicly calls for removing cannabis from Schedule I, citing HHS’s 2023 acknowledgment that cannabis should be reclassified to Schedule III
Effective / Key date: 2026-08-11 (NORML commentary publication)
Status: Not stated in the source
DMV impact: Not stated in the source
NORML has renewed its call to end cannabis’s placement in Schedule I, pointing to a 2023 acknowledgment by the U.S. Department of Health and Human Services (HHS) that federal scheduling should shift to Schedule III. The organization also cites physician attitudes and major scientific reviews indicating therapeutic utility. You can read NORML’s commentary here: “It’s High Time To Remove Cannabis From Schedule I.”
For patients and policymakers across the District, Maryland, and Virginia, the debate is not abstract. Scheduling informs research access, insurance conversations, clinician comfort, and how products and services develop. Below, we unpack what the cited evidence says, how to think about medical use, and what a Schedule I exit could mean in practice for our region.
What does HHS’s 2023 stance actually signal?
HHS acknowledged in 2023 that cannabis should be federally reclassified from Schedule I to Schedule III, according to NORML. In plain terms, that federal health guidance recognizes medical utility and a lower risk profile than Schedule I substances.
This is a consequential marker because Schedule I is reserved for substances presented as lacking accepted medical use and carrying high abuse potential. NORML contrasts cannabis’s risk profile with both other Schedule I substances and widely used, unscheduled substances like alcohol and tobacco. While the commentary does not dictate legal outcomes on its own, it underscores a shift in federal health assessment that is central to how clinicians, researchers, and state programs calibrate their policies.
How strong is medical support for cannabis?
NORML reports that more than nine in ten U.S. healthcare professionals support legal medical access, based on survey data from researchers at the Johns Hopkins University School of Medicine in May (year not stated in the source). NORML also cites polling analyzed by researchers from the Centers for Disease Control and Prevention indicating that over one-quarter of surveyed clinicians have recommended cannabis to patients.
Professional sentiment is not the same as randomized trial evidence, but it does matter for clinical practice. When clinicians endorse a therapy’s availability or report recommending it, it reflects frontline judgments about potential benefits versus risks for particular patients in real-world settings. NORML’s cited figures indicate a medical culture that increasingly treats cannabis as a legitimate therapeutic option, especially where state frameworks allow discussion and access.
Scientific Evidence and Research Findings
NORML references a review by the National Academy of Sciences concluding there is conclusive evidence that cannabis is effective for chronic pain and other serious health conditions. That determination is significant: a national scientific body assessed available evidence and identified clinical domains where efficacy is well-supported. While the commentary does not list individual trials, dosing ranges, or condition-by-condition outcomes, the referenced review positions chronic pain relief as a firmly supported medical use case.
The commentary also notes that other nations already recognize cannabis as medicine and regulate it accordingly. This international perspective matters because global regulatory decisions often track with maturing evidence and accumulated clinical experience. Although the specific countries and frameworks are not enumerated in the commentary, the point is that the United States is not alone in facing decisions about how to organize medical access to cannabis.
Timeline of key signals
Date | Event | What it means |
|---|---|---|
2023 | HHS acknowledged cannabis should be reclassified to Schedule III | Federal health guidance supporting rescheduling |
May (year not stated) | Johns Hopkins researchers report >9 in 10 clinicians support legal medical use | Broad professional support for medical access |
2026-08-11 | NORML commentary calls to remove cannabis from Schedule I | Advocacy aligned with scientific and clinical signals |
Medical Applications and Patient Benefits
NORML points to the National Academy of Sciences’ conclusion that cannabis demonstrates conclusive efficacy for chronic pain. For patients navigating persistent pain, this signals a recognized role for cannabinoid-based therapies within a medical context. The commentary also mentions “other serious health conditions,” though it does not enumerate them. For individuals in the DMV considering medical pathways, the practical takeaway is that mainstream scientific review has identified at least one domain—chronic pain—where benefit is strongly supported.
Clinical recommendations are part of the picture. NORML reports that CDC-analyzed polling shows over one-quarter of surveyed clinicians have recommended cannabis. This suggests that, in appropriate cases and within applicable state frameworks, clinicians are already discussing cannabis with patients. If federal scheduling changes proceed, it could further normalize these conversations, influence continuing medical education, and support more consistent patient counseling about delivery methods, dosing strategies, and product selection within state programs.
Safety Considerations and Side Effects
The NORML commentary does not catalog side effects or risk profiles in detail. It emphasizes that cannabis does not carry the same health risks as Schedule I substances like heroin and contrasts it with unscheduled, widely used substances such as cigarettes and alcohol. For patients, the practical safety step is to work with a clinician who understands your medical history and local program rules before initiating or modifying any cannabis regimen. If you already use cannabis products, keep your healthcare team informed so they can monitor outcomes and advise you responsibly.
What would removing Schedule I change for patients?
The NORML piece focuses on the need to move cannabis out of Schedule I and notes HHS’s 2023 acknowledgment that Schedule III would be appropriate. While it does not list operational changes, a shift away from Schedule I generally aligns with increased recognition of medical utility and can influence how institutions approach research and clinical guidance. Patients often experience those shifts as clearer clinical conversations and evolving program structures within their states.
What this means for DC, Maryland and Virginia
The NORML commentary does not specify DMV policy changes. However, if federal scheduling moves away from Schedule I, it would likely matter for our region’s clinicians and patients by reinforcing the legitimacy of medical conversations already happening. In practice, that could support better patient education on topics you ask us about every day—like differences among THC delivery methods, how patients and caregivers think about medical marijuana delivery services, and where product formats such as pre-rolls, edibles, and concentrates may fit within a clinician-advised plan. For Virginia residents, continued attention to Virginia cannabis regulations will remain essential as frameworks evolve. The commentary does not describe Virginia decriminalization or other state-level provisions.
Bud Lords Take
Our read: Keeping cannabis in Schedule I is increasingly out of step with how medical professionals and scientific bodies characterize its utility—particularly for chronic pain. The HHS acknowledgment in 2023 is a key signal. Moving toward a status that recognizes medical value should help align research access and clinical practice. For patients across the DMV, that alignment could translate into more consistent guidance from healthcare teams and less ambiguity in navigating state programs and services. Because the commentary does not outline implementation timelines or specific federal actions, we advise patients and caregivers to follow official updates and stay in close contact with clinicians for individualized advice.
How can patients talk to clinicians about cannabis?
Two steps usually help: bring a clear list of symptoms and goals, and share any cannabis products you currently use. NORML cites professional support for legal medical access and reports that a substantial minority of clinicians have recommended cannabis, which suggests many providers are open to structured discussions within the bounds of state programs and medical standards.
Does this mean cannabis is already moved to Schedule III?
No. The commentary reports that HHS acknowledged in 2023 that cannabis should be reclassified to Schedule III, but it does not state that rescheduling has taken effect.
What medical condition has strong evidence?
NORML references a National Academy of Sciences review concluding conclusive evidence for chronic pain relief. Other conditions are not detailed in the commentary.
Do U.S. clinicians support medical cannabis?
Yes, according to NORML: more than nine in ten healthcare professionals support its legal medical use (Johns Hopkins researchers, May; year not stated), and CDC-analyzed polling indicates over one-quarter of surveyed clinicians have recommended cannabis.
Is delivery of cannabis legal in my city?
The commentary does not address delivery or local legality. Always check current local rules and consult official state resources before using any patient delivery services.
Resources for further medical consultation
If you’re considering cannabinoid therapy, the safest path is to speak with a licensed healthcare professional familiar with your conditions and local program rules. The NORML commentary links to a fact sheet on rescheduling myths versus reality, which can help frame expectations while policy evolves.
Where does this leave patients right now?
NORML’s position reflects a growing alignment among a federal health agency’s 2023 acknowledgment, clinician attitudes, and a major scientific review on chronic pain. The timing and specifics of any federal change are not included in the commentary. For DMV readers, stay informed, document your health goals, and keep your care team in the loop as you evaluate product formats and delivery methods within your state’s rules. That way, if and when scheduling changes occur, you’re ready to make medically grounded decisions under professional guidance.
Additional context for product formats
While the commentary does not discuss forms or dosing, patients often encounter choices across inhaled products (like pre-rolls) and non-inhaled formats (such as edibles or concentrates). Discuss these options with your clinician before making changes. If you have questions about medical marijuana delivery or how patient delivery services fit into your care journey, bring them to your next appointment so your care team can advise within your state’s framework.
Scientific citations and attribution
This article is based on, and attributes facts to, NORML’s published commentary: It’s High Time To Remove Cannabis From Schedule I. The commentary cites survey work by researchers at the Johns Hopkins University School of Medicine (May; year not stated), clinician polling analyzed by researchers from the Centers for Disease Control and Prevention, a National Academy of Sciences review identifying conclusive evidence for chronic pain, and international recognition of cannabis as a medicine.
Have a cannabis story, local update, or strain you want our newsroom to cover? Request a story →
Written by Science Sage AI
Bud Lords AI Cannabis News Writer
Research-focused voice that translates complex studies into plain English. Covers medical research, cultivation science, and health topics.
Expertise: science · medical
This AI-assisted article was created using the named Bud Lords newsroom personality and reviewed under Bud Lords editorial standards.
Comments